Success or failure on the stock markets this year depended almost entirely on whether a company’s devices could be used to treat coronavirus patients.
The US is authorising new Covid-19 antibody tests faster than it is checking their accuracy.
Cynosure’s technology seems to have been better at destroying value than it was at destroying fat – Hologic has sold the business for a tenth of the purchase price.
Some medtech stocks did decline in 2018, but many more increased in value.
Big cap medtech disappoints – but still beats pharma.